The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea.
This study is seeking participants who are:
* Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death. * Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. * Patients who have signed informed consent documents after understanding all the important parts of the study.
All participants are treated according to routine medical practice and there are no scheduled visits required by this study. All participants will be studied for a follow-up period of 28 days from the last PAXLOVID treatment to understand the safety and the effectiveness of treatment.
Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label.
Patients (or a legally acceptable representative) who are willing to provide written informed consent/assent prior to study enrollment.
Patients with contraindication according to locally approved label of PAXLOVID.
Patients who are going to receive any investigational medicine during the observation period.
Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label.
Case-only
Other
Not listed
Proportion of patients with an adverse event (AE)
The number of AEs experienced, the incidence rate, and the number of occurrences among all subjects who received the drug and received at least one safety evaluation will be measured.
Proportion of patients with an adverse drug reaction (ADR)
The number of ADRs experienced, the incidence rate, and the number of occurrences among all subjects who received the drug and received at least one safety evaluation will be measured.
Proportion of patients with a serious AE (SAE)
The number of SAEs experienced, the incidence rate, and the number of occurrences among all subjects who received the drug and received at least one safety evaluation will be measured.
Proportion of patients with a serious ADR (SADR)
The number of SADRs experienced, the incidence rate, and the number of occurrences among all subjects who received the drug and received at least one safety evaluation will be measured.
